Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 132Myelodysplastic Syndromes 57Leukemia 32Leukemia, Myelomonocytic, Chronic 23Recurrence 18Lymphoma, Large B-Cell, Diffuse 10Myeloproliferative Disorders 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Neoplasms 8Congenital Abnormalities 7Primary Myelofibrosis 6Melanoma 6Hodgkin Disease 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Ovarian Neoplasms 5Blast Crisis 5Thrombocythemia, Essential 4Polycythemia Vera 4Myelodysplastic-Myeloproliferative Diseases 4Lymphoma 4Leukemia, Monocytic, Acute 4Leukemia, Biphenotypic, Acute 4Anemia, Refractory, with Excess of Blasts 4Neoplasm Metastasis 3Leukemia, Myelomonocytic, Acute 3Leukemia, Myeloid, Accelerated Phase 3Head and Neck Neoplasms 3Fallopian Tube Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2

Interventions

Carboplatin 5pembrolizumab 4Trastuzumab 4Oxaliplatin 4Fluorouracil 4Cyclophosphamide 4Radiotherapy 3Paclitaxel 3Endoscopy 3Docetaxel 3Cytarabine 3Chemoradiotherapy 3Capecitabine 3toripalimab 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Observation 2Neoadjuvant Therapy 2Metformin 2Magnetic Resonance Imaging 2Leucovorin 2Irinotecan 2Immunotherapy 2Immune Checkpoint Inhibitors 2Epirubicin 2Drug Therapy 2Doxorubicin 2Cisplatin 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pathologic Complete Response × Decitabine × Clear all
NCT03417427 2020-04-27

A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML

Nanfang Hospital, Southern Medical University

Phase 2 Unknown
100 enrolled
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡